Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
Introduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. Methods: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement. Results: Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had ≥ 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009). Conclusion: Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 99(2020), Seite 491-495 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Timothée Klopfenstein [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.1016/j.ijid.2020.08.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ047877871 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ047877871 | ||
| 003 | DE-627 | ||
| 005 | 20230308130953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.08.024 |2 doi | |
| 035 | |a (DE-627)DOAJ047877871 | ||
| 035 | |a (DE-599)DOAJ211ce617ac594aca973c24253504e282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Timothée Klopfenstein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. Methods: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement. Results: Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had ≥ 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009). Conclusion: Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Invasive mechanical ventilation | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Souheil Zayet |e verfasserin |4 aut | |
| 700 | 0 | |a Anne Lohse |e verfasserin |4 aut | |
| 700 | 0 | |a Phillippe Selles |e verfasserin |4 aut | |
| 700 | 0 | |a Hajer Zahra |e verfasserin |4 aut | |
| 700 | 0 | |a N’dri Juliette Kadiane-Oussou |e verfasserin |4 aut | |
| 700 | 0 | |a Lynda Toko |e verfasserin |4 aut | |
| 700 | 0 | |a Pierre-Yves Royer |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Charles Balblanc |e verfasserin |4 aut | |
| 700 | 0 | |a Vincent Gendrin |e verfasserin |4 aut | |
| 700 | 0 | |a Thierry Conrozier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 99(2020), Seite 491-495 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2020 |g pages:491-495 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.08.024 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/211ce617ac594aca973c24253504e282 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971220306536 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2020 |h 491-495 | ||